Venous thromboembolism in patients with dermatomyositis and polymyositis

被引:1
作者
Selva-O'Callaghan, A. [1 ]
Fernandez-Luque, A. [1 ]
Martinez-Gomez, X. [2 ]
Labirua-Iturburu, A. [1 ]
Vilardell-Tarres, M. [1 ]
机构
[1] Vall DHebron Gen Hosp, Dept Internal Med, Barcelona, Spain
[2] Vall DHebron Gen Hosp, Dept Prevent Med & Epidemiol, Barcelona, Spain
关键词
dermatomyositis; polymyositis; inflammatory myopathy; venous thromboembolism; cancer; intravenous immunoglobulins; THROMBOSIS; MYOSITIS; DISEASE; EVENTS;
D O I
暂无
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective. To assess the incidence of venous thromboembolic events in dermatomyositis and polymyositis patients, and associated factors. Methods. We retrospectively studied a cohort of 123 myositis patients (87 dermatomyositis, 36 polymyositis) from a single centre and identified cases with deep vein thrombosis and/or pulmonary embolism. Type of myositis, association with cancer, presence of thrombophilia, disease activity, and intravenous immunoglobulin therapy were analysed. Incidence rates were calculated on the basis of time to first venous thrombotic event. Patients with less than 12 months' follow-up were excluded. Results. Six new first thromboembolic events occurred in 6 of 96 patients studied (6.3%), all with dermatomyositis. Median time to development of venous thromboembolism was 4.3 months (IQR, 0.8-8.8) after the dermatomyositis diagnosis. Venous thromboembolism was significantly associated with intravenous immunoglobulin therapy (p < 0.05) and older age (p < 0.05), but not with cancer. All events (100%) occurred during active myositis. The incidence density of venous thromboembolism among patients with dermatomyositis according to the first year of follow-up was 9.3 per 1000 person-years (95% CI, 3.4 to 20.3). Conclusion. A trend toward venous thromboembolism was detected in patients with dermatomyositis.
引用
收藏
页码:846 / 849
页数:4
相关论文
共 15 条
[1]   POLYMYOSITIS AND DERMATOMYOSITIS .2. [J].
BOHAN, A ;
PETER, JB .
NEW ENGLAND JOURNAL OF MEDICINE, 1975, 292 (08) :403-407
[2]   A CONTROLLED TRIAL OF HIGH-DOSE INTRAVENOUS IMMUNE GLOBULIN INFUSIONS AS TREATMENT FOR DERMATOMYOSITIS [J].
DALAKAS, MC ;
ILLA, I ;
DAMBROSIA, JM ;
SOUEIDAN, SA ;
STEIN, DP ;
OTERO, C ;
DINSMORE, ST ;
MCCROSKY, S .
NEW ENGLAND JOURNAL OF MEDICINE, 1993, 329 (27) :1993-2000
[3]  
Fendler C, 2010, CLIN EXP RHEUMATOL, V28, pS164
[4]   Deep Venous Thrombosis in Dermatomyositis [J].
Gaitonde, Shilpa D. ;
Ballou, Stanley P. .
JOURNAL OF RHEUMATOLOGY, 2008, 35 (11) :2288-2288
[5]  
Guijarro Merino Ricardo, 2008, Med Clin (Barc), V131 Suppl 2, P2
[6]   International consensus outcome measures for patients with idiopathic inflammatory myopathies. Development and initial validation of myositis activity and damage indices in patients with adult onset disease [J].
Isenberg, DA ;
Allen, E ;
Farewell, V ;
Ehrenstein, MR ;
Hanna, MG ;
Lundberg, IE ;
Oddis, C ;
Pilkington, C ;
Plotz, P ;
Scott, D ;
Vencovsky, J ;
Cooper, R ;
Rider, L ;
Miller, F .
RHEUMATOLOGY, 2004, 43 (01) :49-54
[7]   Brief communication: High incidence of venous thrombotic events among patients with Wegener granulomatosis: The Wegener's clinical occurrence of thrombosis (WeCLOT) study [J].
Merkel, PA ;
Lo, GH ;
Holbrook, JT ;
Tibbs, AK ;
Allen, NB ;
Davis, JC ;
Hoffman, GS ;
McCune, J ;
St Clair, EW ;
Specks, U ;
Spiera, R ;
Petri, M ;
Stone, JH .
ANNALS OF INTERNAL MEDICINE, 2005, 142 (08) :620-626
[8]   Is inflammatory bowel disease an independent and disease specific risk factor for thromboembolism? [J].
Miehsler, W ;
Reinisch, W ;
Valic, E ;
Osterode, W ;
Tillinger, W ;
Feichtenschlager, T ;
Grisar, J ;
Machold, K ;
Scholz, S ;
Vogelsang, H ;
Novacek, G .
GUT, 2004, 53 (04) :542-548
[9]   Venous and arterial thrombosis following administration of intravenous immunoglobulins [J].
Paran, D ;
Herishanu, Y ;
Elkayam, O ;
Shopin, L ;
Ben-Ami, R .
BLOOD COAGULATION & FIBRINOLYSIS, 2005, 16 (05) :313-318
[10]  
Sontheimer Richard D., 1999, Current Opinion in Rheumatology, V11, P475, DOI 10.1097/00002281-199911000-00006